



Characterization of brain tumor initiating cells isolated from an animal model of CNS primitive neuroectodermal tumors

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Morphological analysis of the TCL derived tumors in motor cortex and cerebellum. (A1) HE 10x (motor cortex: LCAS-RTL(138) 7 weeks post-injection), (A2) HE 40x (motor cortex: LCAS-RTL(138) 7 weeks post-injection (invasion area)), (A3) HE 40x (motor cortex: LCAS-RTL(138) 7 weeks post-injection (surface area)), (A4) HE 10x (motor cortex: LC26-RTL(170) 7 weeks post-injection - superficial growth of a tumor characterized by undifferentiated small round blue cells. Foci of perivascular invasion of tumor cells is observed within the adjacent brain parenchyma; (B1) HE 20x (motor cortex: LC26-RTL(170) 7 weeks post-injection (invasion area)), (B2) HE 20x (motor cortex: LC26-RTL(170) 7 weeks post-injection (surface area)), (B3) HE 10x (cerebellum: LC26-RTL(170) 7 weeks post-injection), (B4) HE 20x (cerebellum: LC26-RTL(170) 7 weeks post-injection - a tumor mass grows superficially in motor cortex, extensive invades the adjacent, brain parenchyma and disseminates throughout the ventricular system reaching the cerebellum and extensively infiltrating it.



Supplementary Figure 2: RNA-seq PCA. Score plot of the first principal component (PC1) versus second principal component PC2 from PCA of the 1000 most varied genes. These two components describe around 77% of the total variation. PC1 explains 56.6% of the total variation and demonstrates a grouping of TL and R samples, separated with RT. PC2 distinguishes the three TL samples with the three R samples.

Supplementary Table 1: RT-PCR primer sequences

Gene	Forward primer (5' → 3')	Reverse primer (5' → 3')
CD44	CTGCCGCTTGCAGGTGTA	CATTGGGCAAGGTGCTATT
cMYC	CCTACCCTCTCAACGACAGC	TTGTCCTCCTCAGAGTCGC
Vimentin	AGTCCACTGAGTACCGGAGAC	CATTCACGCATCTGGCGTTC
Sox2	GCCGAGTGGAAACTTTGTCG	GGCAGCGTGTACTTATCCTTCT
BLBP	GTGGAAATGTGACCAAACC	CTTGCCATCCCATTCTGT
Nestin	CAGGAGAACAGGGCCTACA	TGGGAGCAAAGATCCAAGAC
OCT3/4	GGAAGGTATTCAAGCAAACG	CTCCAGGTTGCCTCTCACTC
OTX2	CATGCAGAGGTCTATCCCAT	AAGCTGGGACTGATTGAGAT
NR2F1	AAAGCCATCGTGTGTTCAC	TGCAGGCTCTCGATGTGG
Prame	CAGGACTTCTGGACTGTATGGT	CTACGAGCACCTCTACTGGAA
HEY1	GTTCGGCTCTAGGTTCCATGT	CGTCGGCGCTTCTCAATTATTC
Elongin C	CATCAGGCACGATAAAAGCCA	GCTGTTAGTGTAGCGAACCTTG
ANXA1	CTAAGCGAAACAATGCACAGC	CCTCCTCAAGGTGACCTGTAA
ANXA2	CTCTACACCCCCAAGTGCAT	TCAGTGCTGATGCAAGTTCC
Humanin	TGACACATGTTAACGGCCG	AGGRCTTCTCGTCTTGCTG
EPHA3	ACTCTACGAGACTGCAATAGCA	TCCCCAAGARCCATTGAGTG
NRP1	ACGTGGAAGTCTCGATGGAG	CACCATGTGTTCGTAGTCAGA
KDM4c	CGAGGTGGAAAGTCCTCTGAA	GGGCTCCTTAGACTCCATGTAT
KDM5b	AGTGGGCTCACATATCAGAGG	CAAACACCTTAGGCTGTCTCC
KDM5c	TCAGTGACAGTAAACGGCACC	ACACCGGCATCACATTAGGT
HDAC	AGTAGAGAGGCATCGCAGAGA	GGAGTGTCTTCGTTGCTGAT
MAX	GGAGAGCGACGCTGACAAAC	AGGTGTGGCATTCTGCATC
MINA53	CCACATACTATGGGCCCTGT	TGAAACTGAATCGTTGCCCTT
EMP1	CCACTTCTGGGTATGCACT	TTGCCAGAACTTGTACCGCT
EMP3	CCTGAATCTCTGGTACGACTGC	GCCATTCTCGCTGACATTACTG
TGFB1	CTTCGCCCCTAGCAACGAG	TGAGGGTCATGCCGTGTTTC
ANXA2	CTCTACACCCCCAAGTGCAT	TCAGTGCTGATGCAAGTTCC
GTF2H1	GACCTTGTGTGAGTCAGTGA	CCTGCTTATGATTGGATGTGGAA
ENO1	TGATCGAGATGGATGGAACA	GCAGGATGACTTCAGAGTTGC
CTSC	TTGTTCATGCAGCTGGAAC	TCACCAGGACTCCTTGCAT
LOX	CGGCGGAGGAAAACGTCT	TCGGCTGGTAAGAAATCTGA
MALT1	ACCGCCAATATTGTGTTGG	TGCAACTTCATCCAGTAACACA
TRX1	GTGAAGCAGATCGAGAGCAAG	CGTGGCTGAGAAGTCAACTACTA
P53	GCTTCCCTGGATTGGCAGC	GAGCTTCATCTGGACCTGGG
TRIM22	CTGTCCTGTGRGRCAAGACAG	TGTGGGCTCATCTGACCTCT
DKK3	AGGACACGCAGCACAATTG	CCAGTCTGGTGTGGTTATCTT
PEA15	GGAGAGCCACAACAAGCTG	CCATAGTGAGTAGGTAGGACG
CAV1	ACCCACTTTGAAGCTGTTG	GAACATTGAAATTGGCACCAGG
ACAD11	TTGGATTCCCCGTTCCAAG	AAATCACGGAAGATTGACCC
ACSL3	ATGGAAAACCAACCTCATAGCAA	GCCATCCCAGTTATACCAGCAA
PPAT	AATTGTCAGCCCTCGTTGTT	CCTTAATCGAGCAGCATTACCA
GART	GTGTCTGTGTTCACTGATGGC	GCTGGACAATAGGCTCCCAT
ALDOA	CAAGAAGGACGGAGCTGACT	TTCAAGTCATGGTCCCCATC
GLS	TCTACAGGATTGCGAACGTCT	CTTGTCTAGCATGACACCATCT

Supplementary Table 2: Copy number variations (CNV) and the expression level of the genes resided in the areas affected by CNVs (LC26-RTL(170))

See Supplementary File 1

Supplementary Table 3: Copy number variations (CNV) and the expression level of the genes resided in the areas affected by CNVs (LC25-RTL(293))

See Supplementary File 2

Supplementary Table 4: Copy number variations (CNV) and the expression level of the genes resided in the areas affected by CNVs (LCAS-RTL(138))

See Supplementary File 3

Supplementary Table 5: Single nucleotide polymorphism (SNP): LC25-RTL(293)

See Supplementary File 4

Supplementary Table 6: Single nucleotide polymorphism (SNP): LC26-RTL(170)

See Supplementary File 5

Supplementary Table 7: Single nucleotide polymorphism (SNP): LCAS-RTL(138)

See Supplementary File 6